Shares of Glenmark Pharma tumbled 3 percent in the early trade Tuesday on the back of observations issued by USFDA.
The US Food and Drug Administration has issued 7 observations to company's Baddi units as the company has failed to thoroughly review any unexplained discrepancy and also failure of a batch.
The observations includes, lack of written procedures for production & process controls and complaint records are deficient.
For more information Call us ✆ +91 9111-179961 or Visit Dollar Advisory
The US Food and Drug Administration has issued 7 observations to company's Baddi units as the company has failed to thoroughly review any unexplained discrepancy and also failure of a batch.
The observations includes, lack of written procedures for production & process controls and complaint records are deficient.
For more information Call us ✆ +91 9111-179961 or Visit Dollar Advisory
No comments:
Post a Comment